192 related articles for article (PubMed ID: 27219467)
21. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming.
McEntee CP; Moran HBT; Muñoz-Wolf N; Liddicoat AM; Carroll EC; Erbo-Wern J; Coulter IS; Andersen P; Follmann F; Lavelle EC
Vaccine; 2020 Jan; 38(3):635-643. PubMed ID: 31727505
[TBL] [Abstract][Full Text] [Related]
22. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
Andrew DW; Hafner LM; Beagley KW; Timms P
J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018
[TBL] [Abstract][Full Text] [Related]
23. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Chlamydia-associated ocular disease via a recombinant protein based vaccine in the koala (Phascolarctos cinereus).
Waugh C; Austin R; Polkinghorne A; Timms P
Biologicals; 2016 Nov; 44(6):588-590. PubMed ID: 27707559
[TBL] [Abstract][Full Text] [Related]
25. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
[TBL] [Abstract][Full Text] [Related]
26. Recombinant expression of Chlamydia trachomatis major outer membrane protein in E. Coli outer membrane as a substrate for vaccine research.
Wen Z; Boddicker MA; Kaufhold RM; Khandelwal P; Durr E; Qiu P; Lucas BJ; Nahas DD; Cook JC; Touch S; Skinner JM; Espeseth AS; Przysiecki CT; Zhang L
BMC Microbiol; 2016 Jul; 16(1):165. PubMed ID: 27464881
[TBL] [Abstract][Full Text] [Related]
27. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.
Pal S; Tatarenkova OV; de la Maza LM
Immunology; 2015 Nov; 146(3):432-43. PubMed ID: 26423798
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 17A is an immune marker for chlamydial disease severity and pathogenesis in the koala (Phascolarctos cinereus).
Mathew M; Waugh C; Beagley KW; Timms P; Polkinghorne A
Dev Comp Immunol; 2014 Oct; 46(2):423-9. PubMed ID: 24915607
[TBL] [Abstract][Full Text] [Related]
29. Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.
Sahu R; Verma R; Egbo TE; Giambartolomei GH; Singh SR; Dennis VA
Pathog Dis; 2024 Feb; 82():. PubMed ID: 38862192
[TBL] [Abstract][Full Text] [Related]
30. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.
Dixit S; Singh SR; Yilma AN; Agee RD; Taha M; Dennis VA
Nanomedicine; 2014 Aug; 10(6):1311-21. PubMed ID: 24602605
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets.
Ou C; Tian D; Ling Y; Pan Q; He Q; Eko FO; He C
Int Immunopharmacol; 2013 Aug; 16(4):505-10. PubMed ID: 23669337
[TBL] [Abstract][Full Text] [Related]
33. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.
Pal S; Theodor I; Peterson EM; de la Maza LM
Infect Immun; 2001 Oct; 69(10):6240-7. PubMed ID: 11553566
[TBL] [Abstract][Full Text] [Related]
34. Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum.
Phillips S; Quigley BL; Olagoke O; Booth R; Pyne M; Timms P
Sci Rep; 2020 Jun; 10(1):10152. PubMed ID: 32576914
[TBL] [Abstract][Full Text] [Related]
35. A multi-epitope vaccine based on Chlamydia trachomatis major outer membrane protein induces specific immunity in mice.
Tu J; Hou B; Wang B; Lin X; Gong W; Dong H; Zhu S; Chen S; Xue X; Zhao KN; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2014 May; 46(5):401-8. PubMed ID: 24681882
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of Chlamydia pecorum in Juvenile Koalas ( Phascolarctos cinereus) and Evidence for Protection from Infection via Maternal Immunization.
Russell I; Timms P; Hanger J; Loader J; Gillett A; Waugh C
J Wildl Dis; 2018 Oct; 54(4):863-865. PubMed ID: 29733767
[TBL] [Abstract][Full Text] [Related]
37. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.
Cheng C; Jain P; Bettahi I; Pal S; Tifrea D; de la Maza LM
Vaccine; 2011 Sep; 29(38):6641-9. PubMed ID: 21742006
[TBL] [Abstract][Full Text] [Related]
38. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.
Tifrea DF; Sun G; Pal S; Zardeneta G; Cocco MJ; Popot JL; de la Maza LM
Vaccine; 2011 Jun; 29(28):4623-31. PubMed ID: 21550371
[TBL] [Abstract][Full Text] [Related]
39. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.
Cheng C; Pal S; Tifrea D; Jia Z; de la Maza LM
Microbes Infect; 2014 Mar; 16(3):244-52. PubMed ID: 24291713
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a prototype anti-Chlamydia pecorum recombinant protein vaccine in lambs and pregnant ewes.
Desclozeaux M; Jelocnik M; Whitting K; Saifzadeh S; Bommana S; Potter A; Gerdts V; Timms P; Polkinghorne A
Vaccine; 2017 Jun; 35(27):3461-3465. PubMed ID: 28528762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
